EditorialTofacitinib: A Jak of All Trades
References (20)
- et al.
Natural history of adult ulcerative colitis in population-based cohorts: a systematic review
Clin Gastroenterol Hepatol
(2018) - et al.
Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases
Clin Gastroenterol Hepatol
(2019) - et al.
Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set
Clin Gastroenterol Hepatol
(2018) - et al.
Patient-reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2019) - et al.
Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials
Clin Gastroenterol Hepatol
(2019) - et al.
Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study
Clin Gastroenterol Hepatol
(2018) - et al.
Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea
Clin Gastroenterol Hepatol
(2018) - et al.
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2006) - et al.
Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases
Clin Gastroenterol Hepatol
(2019) - et al.
Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis
Clin Gastroenterol Hepatol
(2019)
There are more references available in the full text version of this article.
Cited by (5)
Preparation and evaluation of dissolving tofacitinib microneedles for effective management of rheumatoid arthritis
2023, European Journal of Pharmaceutical SciencesPharmacology and safety of tofacitinib in ulcerative colitis
2021, Gastroenterologia y HepatologiaIssue Highlights
2019, Clinical Gastroenterology and HepatologyA noduloulcerative plaque in a patient with rheumatoid arthritis
2022, Clinical and Experimental Dermatology
Conflicts of interest This author discloses the following: A.N.A. is supported by funding from the US National Institutes of Health, Crohn’s and Colitis Foundation, Pfizer, and the Chleck Family Foundation. The remaining author discloses no conflicts.
© 2019 by the AGA Institute